Michael Ciesielski and Doctor Robert Fenstermaker are the co-developers for a vaccine that uses the power of the immune system to help fight off Glioblastoma (GBM). This vaccine is targeting a protein found in many cancer cells called survivin, which normally helps the tumor survive. The vaccine will help train the body’s immune system to seek out survivin and kill the tumor cells. Currently, this vaccine is in the clinical trial phase. Some patients in this trial feel optimistic about the outcomes thus far.
GBM is known as one of the most aggressive forms of brain cancer. The tumor’s cells can reproduce quickly and invade into normal brain tissue. This is a difficult tumor to treat and gives a short life expectancy to those who are diagnosed. A GBM is difficult to remove completely and can grow back quickly. At least for the current trials, doctors are saying that newly diagnosed GBM patients are the best candidates for this vaccine.
To learn more about this clinical trial, read the full article here.